ATE396995T1 - 4-oxoimidazolidin-2-spiro piperidin derivat - Google Patents
4-oxoimidazolidin-2-spiro piperidin derivatInfo
- Publication number
- ATE396995T1 ATE396995T1 AT02751627T AT02751627T ATE396995T1 AT E396995 T1 ATE396995 T1 AT E396995T1 AT 02751627 T AT02751627 T AT 02751627T AT 02751627 T AT02751627 T AT 02751627T AT E396995 T1 ATE396995 T1 AT E396995T1
- Authority
- AT
- Austria
- Prior art keywords
- stand
- analgesic
- lower alkyl
- oxoimidazolidine
- reliever
- Prior art date
Links
- QZZYYTLEGVMFDM-UHFFFAOYSA-N 1,4,10-triazaspiro[4.5]decan-3-one Chemical class N1C(=O)CNC11NCCCC1 QZZYYTLEGVMFDM-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229940079593 drug Drugs 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000004084 narcotic analgesic agent Substances 0.000 abstract 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 208000004880 Polyuria Diseases 0.000 abstract 1
- 102100026383 Vasopressin-neurophysin 2-copeptin Human genes 0.000 abstract 1
- 230000000202 analgesic effect Effects 0.000 abstract 1
- 229940124330 analgesic enhancer Drugs 0.000 abstract 1
- 230000001430 anti-depressive effect Effects 0.000 abstract 1
- 239000000935 antidepressant agent Substances 0.000 abstract 1
- 229940005513 antidepressants Drugs 0.000 abstract 1
- 239000002249 anxiolytic agent Substances 0.000 abstract 1
- 230000003925 brain function Effects 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010064 diabetes insipidus Diseases 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 1
- 125000001434 methanylylidene group Chemical class [H]C#[*] 0.000 abstract 1
- 230000004770 neurodegeneration Effects 0.000 abstract 1
- 208000015122 neurodegenerative disease Diseases 0.000 abstract 1
- 229910052757 nitrogen Chemical class 0.000 abstract 1
- 125000004433 nitrogen atom Chemical class N* 0.000 abstract 1
- 239000002762 nociceptin receptor agonist Substances 0.000 abstract 1
- 230000001373 regressive effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/04—Drugs for disorders of the respiratory system for throat disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P23/00—Anaesthetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Anesthesiology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Obesity (AREA)
- Psychology (AREA)
- Child & Adolescent Psychology (AREA)
- Otolaryngology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2001220919 | 2001-07-23 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE396995T1 true ATE396995T1 (de) | 2008-06-15 |
Family
ID=19054667
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT02751627T ATE396995T1 (de) | 2001-07-23 | 2002-07-18 | 4-oxoimidazolidin-2-spiro piperidin derivat |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US7192964B2 (de) |
| EP (1) | EP1420020B1 (de) |
| JP (1) | JP4356453B2 (de) |
| AT (1) | ATE396995T1 (de) |
| CA (1) | CA2454785C (de) |
| DE (1) | DE60226874D1 (de) |
| WO (1) | WO2003010168A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT1491212E (pt) | 2002-03-29 | 2012-11-16 | Mitsubishi Tanabe Pharma Corp | Medicamento para distúrbios de sono |
| AU2003268512A1 (en) | 2002-09-09 | 2004-03-29 | Janssen Pharmaceutica N.V. | Hydroxy alkyl substituted 1,3,8-triazaspiro[4.5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| DE102004014296A1 (de) * | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8-Triazaspiro[4.5]decan-2-on-Verbindingen |
| DE102004014304A1 (de) * | 2004-03-22 | 2005-10-06 | Grünenthal GmbH | Substituierte 1,4,8- Triazaspiro[4,5]decan-2-on-Verbindungen |
| WO2005117862A1 (en) * | 2004-06-03 | 2005-12-15 | Pfizer Limited, | Treatment of urinary conditions including incontinence |
| US20060178390A1 (en) * | 2004-08-02 | 2006-08-10 | Alfonzo Jordan | 1,3,8-Triazaspiro[4,5]decan-4-one derivatives useful for the treatment of ORL-1 receptor mediated disorders |
| DE102005038141A1 (de) * | 2005-08-12 | 2007-02-15 | Grünenthal GmbH | Substituierte 8-(3-Aminopropyl)-1-phenyl-1,3,8-triaza-spiro[4.5]decan-4-on-Derivate |
| ITFE20060036A1 (it) * | 2006-11-23 | 2008-05-24 | Ufpeptides Srl | Agonisti dei recettori nop per il trattamento delle discinesie da levodopa |
| CN101622254B (zh) * | 2006-11-28 | 2013-05-29 | 詹森药业有限公司 | 3-(3-氨基-2-(r)-羟基-丙基)-1-(4-氟-苯基)-8-(8-甲基-萘-1-基甲基)-1,3,8-三氮杂-螺[4.5]癸烷-4-酮的盐 |
| MX2009011006A (es) | 2007-04-09 | 2009-11-02 | Janssen Pharmaceutica Nv | Derivados de 1,3,8-trisustituido-1,3,8-triaza-espiro[4.5]decano-4- ona como ligandos del receptor de orl-1 para el tratamiento de ansiedad y depresion. |
| UA107943C2 (xx) * | 2009-11-16 | 2015-03-10 | Lilly Co Eli | Сполуки спіропіперидину як антагоністи рецептора orl-1 |
| US9044141B2 (en) * | 2010-02-10 | 2015-06-02 | Tokitae Llc | Systems, devices, and methods including a dark-field reflected-illumination apparatus |
| JP6417324B2 (ja) | 2012-07-13 | 2018-11-07 | ペイン セラピューティクス インコーポレイテッド | τリン酸化を阻害する方法 |
| US9433604B2 (en) | 2013-10-08 | 2016-09-06 | Pain Therapeutics Inc. | Method for inhibiting growth of cancer cells |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2575446B2 (ja) | 1988-02-12 | 1997-01-22 | 武田薬品工業株式会社 | トリアザスピロ化合物 |
| PT921125E (pt) * | 1997-12-05 | 2002-06-28 | Hoffmann La Roche | Derivados de 1,38-triaza-espiro 4,5 decan-4-ona |
| EP0997464B1 (de) | 1998-10-23 | 2005-02-16 | Pfizer Inc. | 1,3,8-Triazaspiro[4,5] decanon Verbindungen als orl1-receptor Agonisten |
| JP2000169476A (ja) | 1998-12-09 | 2000-06-20 | Banyu Pharmaceut Co Ltd | ４−オキソイミダゾリジン−５−スピロ−含窒素複素環式化合物 |
| AU1682400A (en) | 1998-12-09 | 2000-06-26 | Banyu Pharmaceutical Co., Ltd. | 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
| AU2001262729A1 (en) | 2000-06-14 | 2001-12-24 | Banyu Pharmaceutical Co., Ltd | 4-oxoimidazolidine-2-spiro-nitrogenous heterocycle compounds |
-
2002
- 2002-07-18 EP EP02751627A patent/EP1420020B1/de not_active Expired - Lifetime
- 2002-07-18 AT AT02751627T patent/ATE396995T1/de not_active IP Right Cessation
- 2002-07-18 CA CA2454785A patent/CA2454785C/en not_active Expired - Fee Related
- 2002-07-18 US US10/484,765 patent/US7192964B2/en not_active Expired - Fee Related
- 2002-07-18 JP JP2003515527A patent/JP4356453B2/ja not_active Expired - Fee Related
- 2002-07-18 DE DE60226874T patent/DE60226874D1/de not_active Expired - Lifetime
- 2002-07-18 WO PCT/JP2002/007292 patent/WO2003010168A1/ja not_active Ceased
-
2006
- 2006-11-22 US US11/603,147 patent/US7557117B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US20070078153A1 (en) | 2007-04-05 |
| US7192964B2 (en) | 2007-03-20 |
| JP4356453B2 (ja) | 2009-11-04 |
| CA2454785C (en) | 2010-09-07 |
| EP1420020B1 (de) | 2008-05-28 |
| US20050004363A1 (en) | 2005-01-06 |
| CA2454785A1 (en) | 2003-02-06 |
| EP1420020A4 (de) | 2005-04-20 |
| WO2003010168A1 (fr) | 2003-02-06 |
| JPWO2003010168A1 (ja) | 2005-02-10 |
| DE60226874D1 (de) | 2008-07-10 |
| EP1420020A1 (de) | 2004-05-19 |
| US7557117B2 (en) | 2009-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60226874D1 (de) | 4-oxoimidazolidin-2-spiro piperidin derivat | |
| ATE303387T1 (de) | Kondensierte imidazolderivate und arzneimittel gegen diabetes mellitus | |
| WO2003095432A1 (en) | Benzimidazole derivatives | |
| MX2009013335A (es) | Derivados de piperidina/piperazina. | |
| SG155180A1 (en) | Derivatives of 4-piperazin-1-yl-4-benzo[b]thiophene suitable for the treatment of cns disorders | |
| WO2002040019A8 (en) | Benzimidazole derivatives | |
| EP1221443A4 (de) | Substituierte imidazolin-derivate | |
| ATE229004T1 (de) | Chinolinische sulfid-derivate als nmda rezeptor- antagonisten und verfahren zu ihrer herstellung | |
| WO2004000808A3 (en) | N-substituted piperidine derivatives as serotonin receptor agents | |
| TW200710086A (en) | Diaryl-substituted hetero 5-membered ring derivatives | |
| EP0915094A4 (de) | Morphinanderivate und ihre medizinische Anwendung | |
| DE60032016D1 (de) | Zyklische aminverbindungen als ccr5-rezeptor antagonisten | |
| DE69705817D1 (de) | (N-(Pyridinylmethyl)-heterozyklische)-ylidenamin-Derivate als Nikotin-Acetylcholin-Rezeptor-Bindemittel | |
| NO20080770L (no) | N-dihydroksyalkylsubstituert 2-oksimidazolderivat | |
| ATE402179T1 (de) | Indolderivate und deren verwendung in medikamenten | |
| DK1438307T3 (da) | Derivater af 4-(thio- eller selenoxanthen-9-yliden)-piperidin eller acridin og anvendelse heraf som selektive 5-HT2Breceptor-antagonister | |
| EP1726590A4 (de) | Cycloalkanopyridinderivat | |
| AU7624494A (en) | Imidazolidinone derivative, acid-addition salt thereof, and remedy for senile dementia | |
| EP1914229A4 (de) | Neuartige cercosporamidderivate | |
| Ting et al. | Synthesis of substituted 4 (Z)-(methoxyimino) pentyl-1-piperidines as dual NK1/NK2 inhibitors | |
| Mete et al. | The discovery of AZD9164, a novel muscarinic M3 antagonist | |
| Williams et al. | Spirocyclic NK1 antagonists II:[4.5]-spiroethers | |
| AU6017800A (en) | Novel amide derivatives | |
| Hayashi et al. | Piperidine derivatives as nonprostanoid IP receptor agonists | |
| DK0940401T3 (da) | 2-Carbonylthiazolderivater og anvendelse deraf |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |